Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle
mass (with or without loss of fat mass) that cannot be fully reversed by conventional
nutritional support and leads to progressive functional impairment.
There is an urgency for improving management, but there is no consensus on the optimal
treatment for cancer cachexia. Several single therapies for cancer cachexia have been
examined in clinical trials, with disappointing overall results. As multiple factors are
responsible for the development of cachexia, it has been argued that optimal cachexia
interventions should target all components: multimodal therapy for a multimodal problem.
The overall aim of this study is to early prevent the development of cachexia rather than
treatment late in the disease trajectory. From a patient perspective a short term effect will
be to improve physical and psychological function, to reduce symptom burden and to improve
survival. In other words live a longer and better life during and after chemotherapy. Direct
effects of the cachexia intervention are expected to be reduction of weight and muscle loss,
and improved physical activity and quality of life.
Phase:
Phase 3
Details
Lead Sponsor:
Norwegian University of Science and Technology
Collaborators:
Beatson West of Scotland Cancer Centre Cancer Research UK Edinburgh Centre Cantonal Hospital of St. Gallen Cedars-Sinai Medical Center Chelsea and Westminister Hospital NHS Cross Cancer Institute Guy's and St Thomas' NHS Foundation Trust Jewish General Hospital Malteser Krankenhaus Seliger Gerhardt NHS Forth Valley Oslo University Hospital Ottawa Regional Cancer Centre Queen Margaret Hospital, Dunfermline St. Olavs Hospital The Beatson West of Scotland Cancer Centre Tumor Biology Center Freiburg Tumor Zentrum Aarau